ZLDPF

Healthcare Biotechnology

Zealand Pharma A/S

$40.00

+1.90 +4.99% today

Price History

Not enough data

Key Stats

Market Cap

2.67B

Avg Volume

499

P/E (TTM)

6.63

EPS

$6.03

52W High

$83.12

52W Low

$35.93

Div. Yield

0.0%

Valuation

Forward P/E

-34.48

P/B Ratio

1.02

P/S Ratio

0.58

EV/EBITDA

-4.85

EV/Revenue

-2.43

Margins

Gross Margin 100.0%

Operating Margin 85.9%

Net Margin 59.0%

EBITDA Margin 50.0%

Growth & Returns

Revenue Growth (YoY)

(50.6%)

Earnings Growth (YoY)

(47.6%)

Earnings Growth (QoQ)

(48.3%)

Return on Equity

16.3%

Return on Assets

7.8%

Liquidity & Leverage

Current Ratio

13.98

Quick Ratio

13.76

Debt / Equity

0.02

Total Cash

14.46B

Total Debt

411.00M

About

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.